Base Grp. (BS.) 銘柄情報

Futures Pointing To Another Lackluster Session On Wall Street

The major U.S. index futures are currently pointing to a roughly flat open on Tuesday, with stocks likely to extend the lackluster performance seen over the course of the previous session...

Form 8-K - Current report

Merck Announces Second-Quarter 2024 Financial Results

Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11% KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding...

U.S. Futures Climb Before Fed Meeting; Oil Prices Drop on China Demand Worries

U.S. index futures rose slightly in pre-market trading on Tuesday, with major corporate earnings and the start of the Federal Reserve’s policy meeting in focus. The Fed’s two-day...

F5 Shares Rise 15%; Diageo Falls 10% on Annual Sales Decline; BP Boosts Dividend and Buyback Program

F5 (NASDAQ:FFIV) – The security and networking solutions company reported adjusted earnings of $3.36 per share in the third fiscal quarter, beating LSEG’s estimate of $2.97 per share...

U.S. Stocks Finish Choppy Trading Session Little Changed

Stocks moved to the upside early in the session on Monday but showed a lack of direction over the course of the trading day. The major averages spent the day bouncing back and forth across the...

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Opinion granted based on positive overall survival and progression-free survival results from the Phase 3 KEYNOTE-A39 trial Positive opinion marks step forward for a potential new first-line...

Merck Announces Fourth-Quarter 2024 Dividend

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common...

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3...

Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024

Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada...